# Thymosin Alpha-1: Frequently Asked Questions

> Thymosin Alpha-1 FAQ — what it is, what it does, whether it is FDA-approved, how it compares to TB-500, the dosing studied, and the honest state of the evidence, cited.

Plain, cited answers to the questions people actually ask about this thymic immune peptide.

## What is thymosin alpha 1?

Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (as part of thymosin fraction 5). Goldstein and colleagues purified it and determined its complete amino-acid sequence in 1977 [1]. It is an immune-modulating peptide; the synthetic, sequence-identical drug version is called thymalfasin.

## Where does thymosin alpha 1 come from in the body?

It is endogenous — your body makes it. It is cut from a larger 113-amino-acid parent protein, prothymosin alpha, and a biochemical study confirmed that cleaving recombinant prothymosin alpha yields mature, acetylated Thymosin Alpha-1 identical to the synthetic form [11]. It was first isolated from calf thymus, and circulating levels decline with age [1].

## What is thymalfasin?

Thymalfasin is the International Nonproprietary Name (the official generic name) for the synthetic version of Thymosin Alpha-1 used in trials and marketed abroad. It is an exact copy of the natural 28-amino-acid sequence, so research on it describes the same molecule [4]. It is approved in roughly 35 countries and not approved in the United States.

## What does thymosin alpha 1 do?

It modulates the immune system. It signals through TLR2 and TLR9 on dendritic cells to drive their maturation and a Th1 (cell-killing) T-cell response, while also activating the IDO pathway to generate regulatory T-cells [5]. The net effect is a dual one: restoring worn-down immunity while damping overreaction. It is not anabolic and does not build muscle.

## What is thymosin alpha 1 used for?

Abroad it is used mainly for chronic hepatitis B and as an immune adjuvant. A cancer reappraisal also positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, acting through dendritic cells and the adaptive immune response [7]. In the US it has no marketing approval and exists only in investigational and compounding contexts.

## Is thymosin alpha 1 FDA-approved?

No. Thymosin Alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States. It is approved as a drug in roughly 35 other countries, but US availability is limited to investigational and compounding settings. The FDA has evaluated related bulk substances for compounding and has not endorsed them [4].

## What is TA1 peptide?

'TA1 peptide' (also written Tα1) is just another name for Thymosin Alpha-1 — the same 28-amino-acid acetylated thymic immune peptide isolated and sequenced by Goldstein and colleagues in 1977 [1]. The 'TA1' shorthand and the 'thymalfasin' drug name both refer to this one molecule, not a different compound.

## Who should not take thymosin alpha 1?

This digest gives no personal guidance, but the literature flags theoretical cautions: people with established autoimmune disease (because it stimulates effector immunity) [16], solid-organ transplant recipients (who are deliberately immunosuppressed) [5], and anyone pregnant or breastfeeding, since dedicated safety data are absent [4]. Those are theoretical concerns, not findings, and any decision belongs with a clinician.

## Is TB-500 the same as thymosin alpha 1?

No. TB-500 is a form of thymosin beta-4, a 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Thymosin Alpha-1 is a 28-amino-acid acetylated immune-modulating peptide [1]. Different sequence, size, mechanism, and use — they share only a family name, and thymosin beta-4 is the one flagged in anti-doping contexts.

## How long should you take thymosin alpha 1?

Trial durations vary by setting and are research data, not advice. A comprehensive review describes multiple-dose regimens over five to seven days for acute settings, the 1.6 mg twice-weekly chronic hepatitis regimen, and, in one cancer study, weekly injection for up to 12 months [4]. There is no general-purpose duration; it depends entirely on the studied indication.

## How long does it take for thymosin alpha 1 to work?

Pharmacologically it acts fast: after a subcutaneous dose in volunteers it peaks in about one to two hours, with an elimination half-life near two hours [4]. Any immune effect, however, is biochemical and builds over a course rather than producing an immediate sensation, which is why many users report not feeling anything. Onset of clinical benefit is study- and indication-specific.

## What is the dosing protocol for thymosin alpha 1?

Reported as research data only: a comprehensive review puts single subcutaneous doses at 0.8 to 6.4 mg and multiple-dose regimens at 1.6 to 16 mg over five to seven days, with 1.6 mg subcutaneous twice weekly the standard chronic hepatitis protocol [4]. Sepsis trials used 1.6 mg every 12 hours [2][3]. These are trial protocols, not personal instructions.

## How does thymosin alpha 1 make you feel?

As an immune modulator, it does not produce a noticeable 'feeling' for most people. Community reports describe either nothing at all or a vague sense of resilience — both anecdotal, not clinical evidence [4]. The most commonly reported physical sensation is mild redness or stinging at the injection site, and occasionally a transient flu-like day.

## How much thymosin alpha 1 should I take?

This site does not provide a human dose. The literature reports studied doses — single subcutaneous doses of 0.8 to 6.4 mg, and 1.6 mg twice weekly as the established hepatitis regimen — strictly as research data tied to specific supervised settings [4]. Extrapolating those to self-administration is unsupported. Any dosing decision belongs with a qualified clinician.

## When is the best time to take thymosin alpha 1?

The literature does not establish an optimal time of day; trial protocols are defined by frequency and duration (for example, 1.6 mg twice weekly, or every 12 hours in sepsis studies) rather than clock timing [4][2]. Timing is therefore not something the evidence speaks to, and this digest offers no scheduling guidance for human use.

## Is thymosin alpha 1 safe to take?

In studied clinical settings it is generally well tolerated; a comprehensive review and large post-marketing surveillance identify mild injection-site reactions, with occasional transient flu-like symptoms, as the dominant adverse events, and no documented organ toxicity at studied doses [4][17]. Separately, research-grade material is unregulated, so purity and identity are not guaranteed — a risk independent of the molecule itself [4].

## Does thymosin alpha 1 help cancer?

It has been studied as an immunostimulatory adjuvant, not a standalone cancer treatment. A reappraisal positions it alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, potentially helping 'turn a cold tumour hot' and easing checkpoint-inhibitor toxicity [7]. The data are preclinical and clinical but heterogeneous; it is an adjunct under study, not an established therapy.

## Is thymosin alpha 1 worth it?

That is a judgment this digest will not make for you, but the evidence picture matters: the strongest, most consistent signal is in chronic viral hepatitis, while the largest, most rigorous sepsis trial (TESTS, 1,106 adults) was null — no significant 28-day mortality benefit, hazard ratio 0.99 [3]. Benefits outside the best-studied settings should not be assumed.

## Does thymosin affect aging?

Circulating Thymosin Alpha-1 levels decline with age, which is part of why vaccine-adjuvant research has explored it against immunosenescence (the age-related weakening of immunity) [1]. That is a rationale and a research direction, not proof of an anti-aging effect; no study in this digest establishes that the peptide slows aging itself.

## Does thymosin alpha 1 reduce the mortality of severe COVID-19?

One retrospective review of 76 severe COVID-19 patients linked treatment to lower mortality (11.11% versus 30.00%, P=0.044) and to restored, less-exhausted T-cells [6]. But a 2022 systematic review of about 5,300 patients found no statistically significant overall mortality benefit. The honest answer: a promising retrospective signal that larger, controlled evidence has not confirmed.

## Has anyone tried thymosin alpha 1 for chronic illness or immune issues?

Community members report using it for immune support and post-viral recovery, with mixed, anecdotal impressions and no controlled outcomes [4]. The formal record is sobering in places: in mouse models the peptide failed to improve lymphocyte immune reconstitution after stem-cell transfer, a notable negative for immune recovery [13]. Reported experience and proven benefit are not the same thing.

## Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?

Thymosin Alpha-1 is a 28-amino-acid acetylated thymic peptide that modulates immunity via dendritic cells and T-cells [1]. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Different sequence, size, mechanism, and use; they are not interchangeable, and thymosin beta-4 is the anti-doping-flagged one.

---

A calm clinical-immunology reading room for the Thymosin Alpha-1 (thymalfasin) record — the dendritic-cell mechanism and the four decades of trials read straight, the strong hepatitis signal and the null sepsis result kept side by side, with no clinic behind the page and nothing here prescribed, dispensed, or sold.